Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

References

• Weinberger AH, Gbedemah M, Martinez AM, et al. Trends in depression prevalence in the USA from 2005 to 2015: widening disparities in vulnerable groups. Psychol Med. 2018;48:1308–1315.
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2163–2196.
   PubMed Web of Science ®Google Scholar
• Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317:1517.
   Web of Science ®Google Scholar
• Greenberg PE, Fournier -A-A, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155–162.
   PubMed Web of Science ®Google Scholar
• Huhn M, Tardy M, Spineli LM, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: A systematic overview of meta-analyses. JAMA Psychiatry. 2014;71:706–715.
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Van Duppen Z. The impact of (the concept of) treatment-resistant depression: an opinion review. International Journal of Neuropsychopharmacology. 2019;22(2):85–92.
   PubMed Web of Science ®Google Scholar
• Thomas L, Kessler D, Campbell J, et al. Prevalence of treatment-resistant depression in primary care: cross-sectional data. British Journal of General Practice. 2013;63(617):852–858.
   PubMed Web of Science ®Google Scholar
• Lindsley CW. New statistics on the cost of new drug development and the trouble with CNS drugs. ACS Chemical Neuroscience. 2014;5(12):1142.
   PubMed Web of Science ®Google Scholar
• Gribkoff VK, Kaczmarek LK. The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes. Neuropharmacology. 2017;120:11–19.
   PubMed Web of Science ®Google Scholar
• Nutt D, Goodwin G. ECNP summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by david nutt and guy goodwin. European Neuropsychopharmacology. 2011;21(7):495–499.
   PubMedGoogle Scholar
• Corrigan-Curay J, McKee AE, Stein SP. Breakthrough-therapy designation — an FDA perspective. New England Journal of Medicine. 2018;378(15):1457–1458.
   PubMed Web of Science ®Google Scholar
• FDA grants Breakthrough Therapy Designation to Usona Institute’s psilocybin program for major depressive disorder [Internet]. 2019 Cited 2019 December 16]. Available from: https://www.businesswire.com/news/home/20191122005452/en/FDA-grants-Breakthrough-Therapy-Designation-Usona-Institutes
   Google Scholar
• Pathways C COMPASS pathways receives FDA breakthrough therapy designation for psilocybin therapy for treatment-resistant depression [internet]. [Cited 2019 December 16]. Available from: https://www.prnewswire.com/news-releases/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression-834088100.html
   Google Scholar
• Feduccia AA, Jerome L, Yazar-Klosinski B, et al. Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Frontiers in Psychiatry. 2019;10. DOI:10.3389/fpsyt.2019.00650.
   PubMed Web of Science ®Google Scholar
• Bahr R, Lopez A, Rey JA. Intranasal esketamine (spravatotm) for use in treatment-resistant depression in conjunction with an oral antidepressant. P T Peer-Rev. J. Formul. Manag. 2019;44:340–375.
   Google Scholar
• Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68–72.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Brexanolone: first global approval. Drugs. 2019;79(7):779–783.
   PubMed Web of Science ®Google Scholar
• Orsolini L, Tomasetti C, Valchera A, et al. Current and future perspectives on the major depressive disorder: focus on the new multimodal antidepressant vortioxetine. CNS & Neurological Disorders - Drug Targets. 2017;16(1):65–92.
   PubMed Web of Science ®Google Scholar
• Heifets BD, Malenka RC. Disruptive psychopharmacology. JAMA Psychiatry. 2019;76(8):775–776.
   PubMed Web of Science ®Google Scholar
• Schenberg EE. Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.Front. Pharmacol. 2018;9:733.
   Google Scholar
• Lee MA, Shlain B. Acid dreams: the complete social history of LSD: the CIA, the sixties, and beyond. Rev. Evergreen ed. New York: Grove Weidenfeld; 1992.
   Google Scholar
• Hendricks PS, Crawford MS, Cropsey KL, et al. The relationships of classic psychedelic use with criminal behavior in the United States adult population. Journal of Psychopharmacology. 2018;32(1):37–48.
   PubMed Web of Science ®Google Scholar
• Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: A systematic review. Journal of Affective Disorders. 2019;258:11–24.
   PubMed Web of Science ®Google Scholar
• Cuijpers P, Sijbrandij M, Koole SL, et al. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13(1):56–67.
   PubMed Web of Science ®Google Scholar
• Watanabe N, Churchill R, Furukawa TA. Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review. BMC Psychiatry. 2007;7(1):18.
   PubMed Web of Science ®Google Scholar
• Morrison AP, Law H, Carter L, et al. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. Lancet Psychiatry. 2018;5(5):411–423.
   PubMed Web of Science ®Google Scholar
• Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.
   PubMed Web of Science ®Google Scholar
• Baltenberger EP, Buterbaugh WM, Martin BS, et al. Review of antidepressants in the treatment of neuropathic pain. Mental Health Clinician. 2015;5(3):123–133.
   Google Scholar
• Kułak-Bejda A, Bejda G, Waszkiewicz N. Antidepressants for irritable bowel syndrome—A systematic review. Pharmacological Reports. 2017;69(6):1366–1379.
   PubMed Web of Science ®Google Scholar
• Yeragani V, Ramachandraih C, Subramanyam N, et al. Antidepressants: from MAOIs to SSRIs and more. Indian Journal of Psychiatry. 2011;53(2):180–182.
   PubMedGoogle Scholar
• Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Experimental and Clinical Psychopharmacology. 2015;23(1):1–21.
   PubMed Web of Science ®Google Scholar
• Hewitt K. Rehabilitating LSD history in postwar America: dilworth Wayne Woolley and the serotonin hypothesis of mental illness. History of Science. 2016;54(3):307–330.
   Web of Science ®Google Scholar
• Nichols DE, Barker EL. Psychedelics. Barker EL, editor. Pharmacological Reviews. 2016;68(2):264–355.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366.
   PubMed Web of Science ®Google Scholar
• Moore TJ, Mattison DR. Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Internal Medicine. 2017;177(2):274–275.
   PubMed Web of Science ®Google Scholar
• Winter SE, Barber JP. Should treatment for depression be based more on patient preference? Patient prefer. Patient Preference and Adherence. 2013;7:1047–1057.
   PubMed Web of Science ®Google Scholar
• Dobscha SK, Corson K, Gerrity MS. Depression treatment preferences of VA primary care patients. Psychosomatics. 2007;48(6):482–488.
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Lam RW, McIntyre RS, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. The Canadian Journal of Psychiatry. 2016;61(9):540–560.
   PubMed Web of Science ®Google Scholar
• Johnson CF, Williams B, MacGillivray SA, et al. ‘Doing the right thing’: factors influencing GP prescribing of antidepressants and prescribed doses. BMC Family Practice. 2017;18(1):72.
   PubMed Web of Science ®Google Scholar
• Elliott C. Listening to prozac: a psychiatrist explores antidepressant drugs and the remaking of the self. BMJ. 1994;308(6945):1724.
   Google Scholar
• Ramsberg J, Asseburg C, Henriksson HM. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. Plos One. 2012;7(8):e42003.
   PubMed Web of Science ®Google Scholar
• Rubio-Valera M, Peñarrubia-María MT, Iglesias-González M, et al. Cost-effectiveness of antidepressants versus active monitoring for mild-to-moderate major depressive disorder: a multisite non-randomized-controlled trial in primary care (INFAP study). The European Journal of Health Economics. 2019;20(5):703–713.
   PubMed Web of Science ®Google Scholar
• Ross EL, Vijan S, Miller EM, et al. The cost-effectiveness of cognitive behavioral therapy versus second-generation antidepressants for initial treatment of major depressive disorder in the United States: a decision analytic model. Annals of Internal Medicine. 2019;171(11):785.
   Web of Science ®Google Scholar
• Andrews PW, Thomson JA, Amstadter A, et al. Primum Non Nocere: an Evolutionary Analysis of Whether Antidepressants Do More Harm than Good. Front. Psychol. 2012;3:117.
   Google Scholar
• Kirsch I. Placebo Effect in the Treatment of Depression and Anxiety. Front. Psychiatry. 2019;10:407.
   Google Scholar
• Hengartner MP. Methodological Flaws. Conflicts of Interest, and Scientific Fallacies: implications for the Evaluation of Antidepressants’ Efficacy and Harm. Front. Psychiatry. 2017;8:275.
   Google Scholar
• Østergaard SD. Do not blame the SSRIs: blame the Hamilton Depression Rating Scale.Acta Neuropsychiatr. 2017;30(5):241–243.
   Google Scholar
• Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. cochrane common mental disorders group, editor. Cochrane Database of Systematic Reviews. 2004. DOI:10.1002/14651858.CD003012.pub2
   PubMedGoogle Scholar
• Sansone RA, Sansone LA, Adherence A. Innov. Clin Neurosci. 2012;9:41–46.
   Google Scholar
• Fava GA. Rational use of antidepressant drugs. Psychotherapy and Psychosomatics. 2014;83(4):197–204.
   PubMed Web of Science ®Google Scholar
• Cartwright C, Gibson K, Read J, et al. Long-term antidepressant use: patient perspectives of benefits and adverse effects. <![cdata[patient Preference and Adherence]]>. 2016;10:1401–1407.
   PubMed Web of Science ®Google Scholar
• Steinkamp JM, Goldblatt N, Borodovsky JT, et al. Technological Interventions for medication adherence in adult mental health and substance use disorders: A systematic review. JMIR Mental Health. 2019;6(3):e12493.
   PubMed Web of Science ®Google Scholar
• Keller MB, Hirschfeld RMA, Demyttenaere K, et al. Optimizing outcomes in depression: focus on antidepressant compliance. International Clinical Psychopharmacology. 2002;17(6):265–271.
   PubMed Web of Science ®Google Scholar
• Masand PS. Tolerability and adherence issues in antidepressant therapy. Clinical Therapeutics. 2003;25(8):2289–2304.
   PubMed Web of Science ®Google Scholar
• Clayton DO, Shen WW. Psychotropic Drug?Induced sexual function disorders. Drug Saf. 1998;19(4):299–312.
   PubMed Web of Science ®Google Scholar
• Brown C, Battista D, Bruehlman R, et al. Beliefs About Antidepressant Medications in Primary Care Patients: relationship to Self-Reported Adherence. Medical Care. 2005;43(12):1203–1207.
   PubMed Web of Science ®Google Scholar
• Iacobucci G. NHS prescribed record number of antidepressants last year. BMJ. 2019;364:l1508.
   PubMed Web of Science ®Google Scholar
• Moore M, Yuen HM, Dunn N, et al. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ. 2009;339(oct15 2):b3999.
   PubMed Web of Science ®Google Scholar
• Fava GA, Belaise C. Discontinuing antidepressant drugs: lesson from a failed trial and extensive clinical experience. Psychotherapy and Psychosomatics. 2018;87(5):257–267.
   PubMed Web of Science ®Google Scholar
• Wentink C, Huijbers MJ, Lucassen P, et al. Discontinuation of antidepressant medication in primary care supported by monitoring plus mindfulness-based cognitive therapy versus monitoring alone: design and protocol of a cluster randomized controlled trial. BMC Family Practice. 2019;20(1):105.
   PubMed Web of Science ®Google Scholar
• Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict. Behav. 2019;97:111–121.
   Google Scholar
• Johnson MW. Psychiatry might need some psychedelic therapy. International Review of Psychiatry. 2018;30(4):285–290.
   PubMed Web of Science ®Google Scholar
• Liu B, Liu J, Wang M, et al. From serotonin to neuroplasticity: evolvement of theories for major depressive disorder. Frontiers in Cellular Neuroscience. 2017;11:305.
   PubMed Web of Science ®Google Scholar
• Felger JC. Role of inflammation in depression and treatment implications. Handb Exp Pharmacol. 2019;250:255–286.
   PubMedGoogle Scholar
• Campbell LF, Norcross JC, Vasquez MJT, et al. Recognition of psychotherapy effectiveness: the APA resolution. Psychotherapy. 2013;50(1):98–101.
   PubMed Web of Science ®Google Scholar
• Imel ZE, Malterer MB, McKay KM, et al. A meta-analysis of psychotherapy and medication in unipolar depression and dysthymia. Journal of Affective Disorders. 2008;110(3):197–206.
   PubMed Web of Science ®Google Scholar
• Craighead WE, Dunlop BW, Craighead WE, Dunlop BW. Combination Psychotherapy and. Combination Psychotherapy and antidepressant medication treatment for depression: for whom, when, and how. . Annual Review of Psychology. 2014;65(1):267–300.
   PubMed Web of Science ®Google Scholar
• Crawford MJ, Thana L, Farquharson L, et al. Patient experience of negative effects of psychological treatment: results of a national survey. British Journal of Psychiatry. 2016;208(3):260–265.
   PubMed Web of Science ®Google Scholar
• Kamenov K, Twomey C, Cabello M, et al. The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. Psychological Medicine. 2017;47(3):414–425.
   PubMed Web of Science ®Google Scholar
• McHugh RK, Whitton SW, Peckham AD, et al. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. The Journal of Clinical Psychiatry. 2013;74(6):595–602.
   PubMed Web of Science ®Google Scholar
• Castelnuovo G, Pietrabissa G, Cattivelli R, et al. Not only clinical efficacy in psychological treatments: clinical psychology must promote cost-benefit, cost-effectiveness, and cost-utility analysis. Frontiers in Psychology. 2016;7:563.
   PubMed Web of Science ®Google Scholar
• Emmelkamp PMG, David D, Beckers T, et al. Advancing psychotherapy and evidence-based psychological interventions: advancing psychotherapy. Int J Methods Psychiatr Res. 2014;23:58–91.
   PubMed Web of Science ®Google Scholar
• Clark DM, Layard R, Smithies R, et al. Improving access to psychological therapy: initial evaluation of two UK demonstration sites. Behav Res Ther. 2009;47:910–920.
   PubMed Web of Science ®Google Scholar
• Layard R, Clark DM. Why more psychological therapy would cost nothing. Front Psychol. 2015;6:1713.
   PubMed Web of Science ®Google Scholar
• Rock PL, Roiser JP, Riedel WJ, et al. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44:2029–2040.
   PubMed Web of Science ®Google Scholar
• Cuijpers P, Cristea IA, Karyotaki E, et al. How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence. World Psychiatry. 2016;15:245–258.
   PubMed Web of Science ®Google Scholar
• Amick HR, Gartlehner G, Gaynes BN, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015;351:h6019.
   PubMed Web of Science ®Google Scholar
• Frank JD. Persuasion and healing: A comparative study of psychotherapy. Thierd ed. Baltimore: Hopkins Univ. Press; 1991.
   Google Scholar
• Brent DA, Kolko DJ. Psychotherapy: definitions, mechanisms of action, and relationship to etiological models. J Abnorm Child Psychol. 1998;26:17–25.
   PubMed Web of Science ®Google Scholar
• Freud S, Brill AA. The history of the psychoanalytic movement. Whitefish, Mont.: Kessinger Pub.; 2007.
   Google Scholar
• Cautin RL. A century of psychotherapy, 1860–1960. In: editors, Norcross JC, VandenBos GR, Freedheim DK. Hist. psychother. contin. change. 2nd ed. Washington: American Psychological Association; 2011.
   Google Scholar
• Robertson D. The philosophy of cognitive-behavioural therapy (CBT): stoic philosophy as rational and cognitive psychotherapy. London: Karnac; 2010.
   Google Scholar
• Clifford T. Tibetan Buddhist medicine and psychiatry: the diamond healing. York Beach, Me: S. Weiser; 1984.
   Google Scholar
• Cuijpers P, Reijnders M, Huibers MJH. The role of common factors in psychotherapy outcomes. Annu Rev Clin Psychol. 2019;15:207–231.
   PubMed Web of Science ®Google Scholar
• Wampold BE. How important are the common factors in psychotherapy? An update. World Psychiatry. 2015;14:270–277.
   PubMed Web of Science ®Google Scholar
• Budd R, Hughes I. The Dodo Bird Verdict-controversial, inevitable and important: a commentary on 30 years of meta-analyses: the dodo bird verdict: a commentary. Clin Psychol Psychother. 2009;16:510–522.
   PubMed Web of Science ®Google Scholar
• Rosenzweig S. Some implicit common factors in diverse methods of psychotherapy. Am J Orthopsychiatry. 1936;6:412–415.
   Google Scholar
• Brown J. Specific techniques vs. common factors? Psychotherapy integration and its role in ethical practice. Am J Psychother. 2015;69:301–316.
   PubMed Web of Science ®Google Scholar
• Frank JD. Therapeutic factors in psychotherapy. Am J Psychother. 1971;25:350–361.
   PubMed Web of Science ®Google Scholar
• Goldstone D. Cognitive-behavioural therapy versus psychodynamic psychotherapy for the treatment of depression: a critical review of evidence and current issues. South Afr J Psychol. 2017;47:84–96.
   Web of Science ®Google Scholar
• Foa EB. Cognitive behavioral therapy of obsessive-compulsive disorder. Dialogues Clin Neurosci. 2010;12:199–207.
   PubMedGoogle Scholar
• Keefe JR, McCarthy KS, Dinger U, et al. A meta-analytic review of psychodynamic therapies for anxiety disorders. Clin Psychol Rev. 2014;34:309–323.
   PubMed Web of Science ®Google Scholar
• Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry. 2004;61:714–719.
   PubMed Web of Science ®Google Scholar
• Mullen LS, Blanco C, Vaughan SC, et al. Defense mechanisms and personality in depression. Depress Anxiety. 1999;10:168–174.
   PubMed Web of Science ®Google Scholar
• Cristea IA, Huibers MJH, David D, et al. The effects of cognitive behavior therapy for adult depression on dysfunctional thinking: A meta-analysis. Clin Psychol Rev. 2015;42:62–71.
   PubMed Web of Science ®Google Scholar
• DeRubeis RJ, Siegle GJ, Hollon SD. Cognitive therapy vs. medications for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci. 2008;9:788–796.
   PubMed Web of Science ®Google Scholar
• Wampold BE, Imel ZE. The great psychotherapy debate: the evidence for what makes psychotherapy work. 2nd ed. New York, NY, US: Routledge/Taylor & Francis Group; 2015.
   Google Scholar
• Kirsch I, Moore TJ, Scoboria A, et al. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev. Treat. 2002;5(1):5.
   Google Scholar
• Leuchter AF, Hunter AM, Tartter M, et al. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. Br J Psychiatry. 2014;205:443–449.
   PubMed Web of Science ®Google Scholar
• Faria V, Gingnell M, Hoppe JM, et al. Do you believe it? Verbal suggestions influence the clinical and neural effects of escitalopram in social anxiety disorder: a randomized trial. EBioMedicine. 2017;24:179–188.
   PubMed Web of Science ®Google Scholar
• Zilcha-Mano S, Roose SP, Barber JP, et al. Therapeutic alliance in antidepressant treatment: cause or effect of symptomatic levels? Psychother. Psychosom. 2015;84:177–182.
   Web of Science ®Google Scholar
• Ankarberg P, Falkenström F. Treatment of depression with antidepressants is primarily a psychological treatment. Psychother Theory Res Pract Train. 2008;45:329–339.
   PubMed Web of Science ®Google Scholar
• Chiarotti F, Viglione A, Giuliani A, et al. Citalopram amplifies the influence of living conditions on mood in depressed patients enrolled in the STAR*D study. Transl Psychiatry. 2017;7:tp201735.
   Web of Science ®Google Scholar
• Viglione A, Chiarotti F, Poggini S, et al. Predicting antidepressant treatment outcome based on socioeconomic status and citalopram dose. Pharmacogenomics J. 2019;19:538.
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Warden D, Trivedi MH, et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60:1439–1445.
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Cipriani A, Cowen PJ, et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6:601–609.
   PubMed Web of Science ®Google Scholar
• Alboni S, van Dijk RM, Poggini S, et al. Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. Mol Psychiatry. 2017;22:552–561.
   PubMed Web of Science ®Google Scholar
• Angermann CE, Gelbrich G, Störk S, et al. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial. JAMA. 2016;315:2683.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Natale P, Ruospo M, et al. Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis.Cochrane Database Syst Rev. 2016;5:CD004541.
   Web of Science ®Google Scholar
• Charney DA, Heath LM, Zikos E, et al. Poorer drinking outcomes with citalopram treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2015;39:1756–1765.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291:1887–1896.
   PubMed Web of Science ®Google Scholar
• Prosser A, Helfer B, Leucht S. Biological v. psychosocial treatments: a myth about pharmacotherapy v. psychotherapy. Br J Psychiatry. 2016;208:309–311.
   PubMed Web of Science ®Google Scholar
• Barsaglini A, Sartori G, Benetti S, et al. The effects of psychotherapy on brain function: A systematic and critical review. Prog Neurobiol. 2014;114:1–14.
   PubMed Web of Science ®Google Scholar
• Koch JM, Hinze-Selch D, Stingele K, et al. Changes in CREB phosphorylation and BDNF plasma levels during psychotherapy of depression. Psychother Psychosom. 2009;78:187–192.
   PubMed Web of Science ®Google Scholar
• Roberts S, Keers R, Lester KJ, et al. HPA AXIS RELATED GENES AND RESPONSE TO PSYCHOLOGICAL THERAPIES: GENETICS AND EPIGENETICS. Depress Anxiety. 2015;32:861–870.
   PubMed Web of Science ®Google Scholar
• Perroud N, Salzmann A, Prada P, et al. Response to psychotherapy in borderline personality disorder and methylation status of the BDNF gene. Transl Psychiatry. 2013;3:e207.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Psychotherapy as an epigenetic “drug”: psychiatric therapeutics target symptoms linked to malfunctioning brain circuits with psychotherapy as well as with drugs. J Clin Pharm Ther. 2012;37:249–253.
   PubMed Web of Science ®Google Scholar
• Doblin RE, Christiansen M, Jerome L, et al. The past and future of psychedelic science: an introduction to this issue. J Psychoactive Drugs. 2019;51:93–97.
   PubMed Web of Science ®Google Scholar
• Pollan M. How to change your mind: what the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence. New York: Penguin Press; 2018.
   Google Scholar
• Liechti ME. Modern clinical research on LSD. Neuropsychopharmacology. 2017;42:2114–2127.
   PubMed Web of Science ®Google Scholar
• Freud S. The interpretation of dreams. New York: Barnes & Noble Books; 1994.
   Google Scholar
• Kaplan RM. Humphry osmond: the psychedelic psychiatrist. Int J Humanit Soc Sci Educ.
   Google Scholar
• Waltz M. From ‘Pathological Motherhood’ to Refrigerator Mothers. In: Waltz M, editor. Autism soc. med. hist. London: Palgrave Macmillan UK; 2013; p. 73–86.
   Google Scholar
• Stockings GT. A clinica study of the mescaline psychosis, with special reference to the mechanism of the genesis of schizophrenic and other psychotic states. J Nerv Ment Dis. 1940;92:678.
   Google Scholar
• Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007;3:495–500.
   PubMedGoogle Scholar
• Woolley DW, Shaw E, Biochemical A. Pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci. 1954;40:228–231.
   PubMed Web of Science ®Google Scholar
• Lindemann E. Psychological changes in normal and abnormal individuals under the influence of sodium amytal. Am J Psychiatry. 1932;88:1083–1091.
   Google Scholar
• Meduna LJ. Carbon dioxide therapy: A neurophysiological treatment of nervous disorders. Springfield: Charles C Thomas Publisher; 1950.
   Google Scholar
• Grinspoon L, Reconsidered: LSD. Should clinical research be resumed? The Sciences. 1981;21:20–23.
   Google Scholar
• Blewet DB, Chwelos MD Handbook for the therapeutic use of LSD-25 [Internet]. 1959 [Cited 2020 January 1]. Available from: https://www.erowid.org/psychoactives/guides/handbook_lsd25.shtml
   Google Scholar
• Sandison RA, Spencer AM, Whitelaw JDA. The therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci. 1954;100:491–507.
   PubMed Web of Science ®Google Scholar
• Sandison RA. Psychological aspects of the lsd treatment of the neuroses. J Ment Sci. 1954;100:508–515.
   PubMed Web of Science ®Google Scholar
• Kraehenmann R, Pokorny D, Vollenweider L, et al. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology (Berl). 2017;234:2031–2046.
   PubMed Web of Science ®Google Scholar
• Barrett FS, Preller KH, Herdener M, et al. Serotonin 2A receptor signaling underlies lsd-induced alteration of the neural response to dynamic changes in music. Cereb Cortex. 2018;28:3939–3950.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011;218:649–665.
   PubMed Web of Science ®Google Scholar
• Osório F, Sanches RF DL, LR M, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr. 2015;37:13–20.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol Oxf Engl. 2008;22:603–620.
   PubMed Web of Science ®Google Scholar
• Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). Bell V, editor. PLoS ONE. 2010;5:e12412.
   PubMed Web of Science ®Google Scholar
• Barrett FS, Johnson MW, Griffiths RR. Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol Oxf Engl. 2015;29:1182–1190.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Muthukumaraswamy S, Roseman L, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A. 2016;113:4853–4858.
   PubMed Web of Science ®Google Scholar
• Holze F, Vizeli P, Müller F, et al. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology. 2019;45:462.
   PubMed Web of Science ®Google Scholar
• Barrett FS, Griffiths RR, Hallucinogens C. Mystical experiences: phenomenology and neural correlates. Curr Top Behav Neurosci. 2018;36:393–430.
   PubMedGoogle Scholar
• Carhart-Harris RL, Kaelen M, Whalley MG, et al. LSD enhances suggestibility in healthy volunteers. Psychopharmacology (Berl). 2015;232:785–794.
   PubMed Web of Science ®Google Scholar
• Dolder PC, Schmid Y, Müller F, et al. LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2016;41:2638–2646.
   PubMed Web of Science ®Google Scholar
• Roseman L, Haijen E, Idialu-Ikato K, et al. Emotional breakthrough and psychedelics: validation of the Emotional Breakthrough Inventory. J Psychopharmacol (Oxf.). 2019;33:1076–1087.
   PubMed Web of Science ®Google Scholar
• Kaelen M, Barrett FS, Roseman L, et al. LSD enhances the emotional response to music. Psychopharmacology (Berl). 2015;232:3607–3614.
   PubMed Web of Science ®Google Scholar
• Preller KH, Herdener M, Pokorny T, et al. The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. Curr Biol. 2017;27:451–457.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol (Oxf.). 2016;30:1181–1197.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Leech R, Hellyer PJ, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014;8:20.
   PubMed Web of Science ®Google Scholar
• Buckner RL, Andrews-Hanna JR, Schacter DL. The brain’s default network: anatomy, function, and relevance to disease. Year Cogn. Neurosci. 2008. Malden: Blackwell Publishing; 2008.
   Google Scholar
• Andrews-Hanna JR The brain’s default network and its adaptive role in internal mentation - jessica r. andrews-hanna, 2012. the neuroscientist. 2011
   Google Scholar
• Karapanagiotidis T, Bernhardt BC, Jefferies E, et al. Tracking thoughts: exploring the neural architecture of mental time travel during mind-wandering. NeuroImage. 2017;147:272–281.
   PubMed Web of Science ®Google Scholar
• Millière R, Carhart-Harris RL, Roseman L, et al. Psychedelics, Meditation, and Self-Consciousness. Front. Psychol. 2018;9:1475.
   Google Scholar
• Carhart-Harris RL, Friston KJ. The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas. Brain. 2010;133:1265–1283.
   PubMed Web of Science ®Google Scholar
• Peters SK, Dunlop K, Downar J. Cortico-striatal-thalamic loop circuits of the salience network: a central pathway in psychiatric disease and treatment. Front Syst Neurosci. 2016;10:104.
   PubMed Web of Science ®Google Scholar
• Preller KH, Razi A, Zeidman P, et al. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proc Natl Acad Sci U S A. 2019;116:2743–2748.
   PubMed Web of Science ®Google Scholar
• Grof S, Hofmann A, Weil A LSD psychotherapy. ben lomond, calif.: multidisciplinary association for psychedelic studies; 2008.
   Google Scholar
• Carhart-Harris RL, Friston KJREBUS. and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019;71:316–344.
   PubMed Web of Science ®Google Scholar
• Müller F, Dolder PC, Schmidt A, et al. Altered network hub connectivity after acute LSD administration. NeuroImage Clin. 2018;18:694–701.
   PubMed Web of Science ®Google Scholar
• Geyer M, Vollenweider F. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci. 2008;29:445–453.
   PubMed Web of Science ®Google Scholar
• de la Torre R, Farré M, Roset PN, et al. Human Pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004;26:137–144.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Wall MB, Erritzoe D, et al. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol. 2014;17:527–540.
   PubMed Web of Science ®Google Scholar
• Ballesta S, Reymond G, Pozzobon M, et al. Effects of MDMA Injections on the behavior of socially-housed long-tailed macaques (macaca fascicularis). PLoS ONE. 2016;11:e0147136.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick M, Delton AW, Robertson TE, et al. Prosocial effects of MDMA: A measure of generosity. J Psychopharmacol Oxf Engl. 2015;29:661–668.
   PubMed Web of Science ®Google Scholar
• Greer G, Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs. 1986;18:319–327.
   PubMed Web of Science ®Google Scholar
• Passie T. The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985). Drug Sci Policy Law. 2018;4:2050324518767442.
   Google Scholar
• Lur G, Fariborzi M, Higley MJ. Ketamine disrupts neuromodulatory control of glutamatergic synaptic transmission Adams MM, editor. PLOS ONE. 2019;14:e0213721.
   PubMed Web of Science ®Google Scholar
• Sleigh J, Harvey M, Voss L, et al. Ketamine – more mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care. 2014;4:76–81.
   Google Scholar
• Moda-Sava RN, Murdock MH, Parekh PK, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364:eaat8078.
   PubMed Web of Science ®Google Scholar
• Haile CN, Murrough JW, Iosifescu DV, et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17:331–336.
   PubMed Web of Science ®Google Scholar
• Domino EF. Taming the ketamine tiger. 1965 Anesthesiology. 2010;113:678.
   Google Scholar
• Hurth KP, Jaworski A, Thomas KB. et al. The reemergence of ketamine for treatment in critically ill adults: crit. Care Med. 2020; 1.
   Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–354.
   PubMed Web of Science ®Google Scholar
• Kryst J, Kawalec P, Mitoraj AM, et al. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol. Rep. 2020. DOI:10.1007/s43440-020-00097-z
   Google Scholar
• Glue P, Neehoff S, Sabadel A. et al. Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study. J Psychopharmacol (Oxf.). 2020;34(3):267.
   Google Scholar
• Hartberg J, Garrett-Walcott S, De Gioannis A. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. Psychopharmacology (Berl). 2018;235:393–398.
   PubMed Web of Science ®Google Scholar
• Wajs E, Aluisio L, Holder R, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. 2020;81.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173:816–826.
   PubMed Web of Science ®Google Scholar
• Phillips JL, Norris S, Talbot J, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry. 2019;176:401–409.
   PubMed Web of Science ®Google Scholar
• Kolp E, Friedman HL. University of florida, et al. ketamine psychedelic psychotherapy: focus on its pharmacology, phenomenology, and clinical applications. Int J Transpers Stud. 2014;33:84–140.
   Google Scholar
• Dore J, Turnipseed B, Dwyer S, et al. Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoactive Drugs. 2019;51:189–198.
   PubMed Web of Science ®Google Scholar
• Busch AK, Johnson WCLSD 25 as an aid in psychotherapy; preliminary report of a new drug. Dis. Nerv. Syst. 1950;11:241–243.
   Google Scholar
• Grof S, Goodman LE, Richards WA, et al. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry. 1973;8:129–144.
   PubMedGoogle Scholar
• Elmer LD, MacDonald DA, Friedman HL. Transpersonal psychology, physical health, and mental health: theory, research, and practice. Humanist Psychol. 2003;31:159–181.
   Google Scholar
• Kasprow MC, Scotton BW. A review of transpersonal theory and its application to the practice of psychotherapy. J Psychother P Res. 1999;8:12.
   PubMedGoogle Scholar
• Bonny HL, Pahnke WN. The use of music in psychedelic (LSD) psychotherapy. J Music Ther. 1972;9:64–87.
   Google Scholar
• Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol (Oxf.). 2016;30:1165–1180.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder. 8.1. 1115 Mission Street Santa Cruz, CA 95060: MAPS Public Benefit Corporation; 2017.
   Google Scholar
• Kolp E, Young MS. Florida mental health institute of university of south florida, et al. ketamine-enhanced psychotherapy: preliminary clinical observations on its effects in treating death anxiety. Int J Transpers Stud. 2007;26:1–17.
   Google Scholar
• Klavetter RE, Mogar RE. Peak experiences: investigation of their relationship to psychedelic therapy and self-actualization. J Humanist Psychol. 1967;7:171–177.
   Web of Science ®Google Scholar
• Taking Psychedelics BI, Seriously J. Palliat. Med. 2018;21:417–421.
   Google Scholar
• Watts R, Luoma JB. The use of the psychological flexibility model to support psychedelic assisted therapy. J Context Behav Sci. 2020;15:92–102.
   Web of Science ®Google Scholar
• Leary T, Metzner R, Dass R, et al. The psychedelic experience: a manual based on the Tibetan book of the dead. New York: Citadel Press; 2007.
   Google Scholar
• Richards WA. Sacred knowledge: psychedelics and religious experiences. New York (NY): Columbia University Press; 2015.
   Google Scholar
• Hartogsohn I. Constructing drug effects: A history of set and setting. Drug Sci Policy Law. 2017;3:2050324516683325.
   Google Scholar
• Strassman R. DMT: the spirit molecule: a doctor’s revolutionary research into the biology of near-death and mystical experiences. Rochester, Vt: Park Street Press; 2001.
   Google Scholar
• Carhart-Harris RL, Roseman L, Haijen E, et al. Psychedelics and the essential importance of context. J Psychopharmacol (Oxf.). 2018;32:725–731.
   PubMed Web of Science ®Google Scholar
• Winnicott DW. Transitional objects and transitional phenomena; a study of the first not-me possession. Int J Psychoanal. 1953;34:89–97.
   PubMed Web of Science ®Google Scholar
• Gross R, Sasson Y, Zarhy M, et al. Healing environment in psychiatric hospital design. Gen Hosp Psychiatry. 1998;20:108–114.
   PubMed Web of Science ®Google Scholar
• Dijkstra K, Pieterse M, Pruyn A. Physical environmental stimuli that turn healthcare facilities into healing environments through psychologically mediated effects: systematic review. J Adv Nurs. 2006;56:166–181.
   PubMed Web of Science ®Google Scholar
• PS S, van Der, Dusseldorp E, FM K, et al. Impact of the physical environment of psychiatric wards on the use of seclusion. Br J Psychiatry. 2013;202:142–149.
   PubMed Web of Science ®Google Scholar
• Zhao K, Bai ZG, Bo A, et al. A systematic review and meta-analysis of music therapy for the older adults with depression. Int J Geriatr Psychiatry. 2016;31:1188–1198.
   PubMed Web of Science ®Google Scholar
• Leubner D, Hinterberger T. Reviewing the effectiveness of music interventions in treating depression. Front Psychol. 2017;8:1109.
   PubMed Web of Science ®Google Scholar
• Hoffer A. D-Lysergic acid diethylamide (LSD): A review of its present status. Clin Pharmacol Ther. 1965;6:183–255.
   PubMed Web of Science ®Google Scholar
• Watts R, Day C, Krzanowski J, et al. Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. J Humanist Psychol. 2017;57:520–564.
   Web of Science ®Google Scholar
• Kaelen M, Giribaldi B, Raine J, et al. The hidden therapist: evidence for a central role of music in psychedelic therapy. Psychopharmacology (Berl). 2018;235:505–519.
   PubMed Web of Science ®Google Scholar
• Richards DA, Ekers D, McMillan D, et al. Cost and outcome of behavioural activation versus cognitive behavioural therapy for depression (COBRA): a randomised, controlled, non-inferiority trial. Lancet. 2016;388:871–880.
   PubMed Web of Science ®Google Scholar
• Moreno FA, Wiegand CB, Taitano EK, et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735–1740.
   PubMed Web of Science ®Google Scholar
• Grob CS, Danforth AL, Chopra GS, et al. PIlot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71–78.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction. J Psychopharmacol Oxf Engl. 2014;28:983–992.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619–627.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol (Oxf.). 2018;32:49–69.
   PubMed Web of Science ®Google Scholar
• Lyons T, Carhart-Harris RL. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. J Psychopharmacol (Oxf.). 2018;32:811–819.
   PubMed Web of Science ®Google Scholar
• Erritzoe D, Roseman L, Nour MM, et al. Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand. 2018;138:368–378.
   PubMed Web of Science ®Google Scholar
• Studerus E, Gamma A, Kometer M, et al. Prediction of psilocybin response in healthy volunteers. PLoS ONE. 2012;7:e30800.
   PubMed Web of Science ®Google Scholar
• Haijen ECHM, Kaelen M, Roseman L, et al. Predicting responses to psychedelics: a prospective study. Front Pharmacol. 2018;9:897.
   PubMed Web of Science ®Google Scholar
• Hendricks PS, Clark CB, Johnson MW, et al. Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. J Psychopharmacol (Oxf.). 2014;28:62–66.
   PubMed Web of Science ®Google Scholar
• Walsh Z, Hendricks PS, Smith S, et al. Hallucinogen use and intimate partner violence: prospective evidence consistent with protective effects among men with histories of problematic substance use. J Psychopharmacol (Oxf.). 2016;30:601–607.
   PubMed Web of Science ®Google Scholar
• Thiessen MS, Walsh Z, Bird BM. et al. Psychedelic use and intimate partner violence: the role of emotion regulation. J Psychopharmacol (Oxf.). 2018; 0269881118771782.
   Web of Science ®Google Scholar
• Passie T, Halpern JH, Stichtenoth DO, et al. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14:295–314.
   PubMed Web of Science ®Google Scholar
• Lowe LM, Peterson BL, Couper FJ. A case review of the first analytically confirmed 25i-nbome-related death in washington state. J Anal Toxicol. 2015;39:668–671.
   PubMed Web of Science ®Google Scholar
• Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376:1558–1565.
   PubMed Web of Science ®Google Scholar
• Krebs TS, Johansen PO. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol (Oxf.). 2012;26:994–1002.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Feduccia AA, Jerome L, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019;236:2735–2745.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Wagner MT, Mithoefer AT, et al. The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol (Oxf.). 2011;25:439–452.
   PubMed Web of Science ®Google Scholar
• Mithoefer MC, Wagner MT, Mithoefer AT, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol Oxf Engl. 2013;27:28–39.
   PubMed Web of Science ®Google Scholar
• Danforth AL, Grob CS, Struble C, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl). 2018;235:3137–3148.
   PubMed Web of Science ®Google Scholar
• Cooper MD, Rosenblat JD, Cha DS, et al. Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review. World J Biol Psychiatry. 2017;18:410–423.
   PubMed Web of Science ®Google Scholar
• Ross C, Jain R, Bonnett CJ, et al. High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Ann Clin Psychiatry. 2019;31:271.
   PubMed Web of Science ®Google Scholar
• Kolp E, Friedman HL, Young MS, et al. Ketamine enhanced psychotherapy: preliminary clinical observations on its effectiveness in treating alcoholism. Humanist Psychol. 2006;34:399–422.
   Google Scholar
• Krupitsky E, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat. 2002;23:273–283.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Nunes EV, Hart CL, et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry. 2019;176:923.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lin D, Wu B, et al. Ketamine abuse potential and use disorder. Brain Res Bull. 2016;126:68–73.
   PubMed Web of Science ®Google Scholar
• McAndrew A, Lawn W, Stevens T, et al. A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial. Trials. 2017;18:159.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Nunes EV, Hart CL, et al. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: results from a randomized, controlled laboratory study. Neuropharmacology. 2018;142:270–276.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Anerella C, Hart CL, et al. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend. 2014;136:153–157.
   PubMed Web of Science ®Google Scholar
• Sos P, Klirova M, Novak T, et al. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett. 2013;34:287–293.
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Shovestul BJ, Jaso BA, et al. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Disord. 2018;232:310–315.
   PubMed Web of Science ®Google Scholar
• Michaels TI, Purdon J, Collins A, et al. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18:245.
   PubMed Web of Science ®Google Scholar